Poor Responders Infertile Patients -A Great Clinical Challenge
NCT ID: NCT03402620
Last Updated: 2018-06-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
102 participants
INTERVENTIONAL
2018-01-11
2018-06-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Growth Hormone Supplementation With Gonadotrophins in IVF/ICSI for Poor Responders
NCT03759301
Comparative Study Between Single Versus Dual Trigger for Poor Responders in GnRH-antagonist ICSI Cycles
NCT04008966
IVF/ICSI Protocols in Poor Responders With Growth Hormone
NCT01897324
Antagonist Protocol in Poor Responders
NCT02195947
Extended Letrozole Regimen Co-treatment With Gonadotropin Releasing Hormone Antagonist Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in Poor Responders Undergoing IVF-ET
NCT04268927
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
four ampoules group
gonadotropin starting dose is 4 ampoules daily
Gonadotropins
Human menopausal gonadotropin 75 IU ampoules start at cycle day 2
six ampoules group
gonadotropin starting dose is 6 ampoules daily
Gonadotropins
Human menopausal gonadotropin 75 IU ampoules start at cycle day 2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gonadotropins
Human menopausal gonadotropin 75 IU ampoules start at cycle day 2
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age \>40 years or other cause of poor function.
2. AFC\<2-5 in both ovaries or AMH \< 0.5-1.1 ng/dl 2)
3. History of poor response with conventional stimulation protocol
Exclusion Criteria
2. Severe male factor.
3. Endometriosis.
20 Years
44 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Maged
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmed Maged, MD
Role: PRINCIPAL_INVESTIGATOR
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kasr Alainy medical school
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.